A Phase 4 interventional study of piperacillin-tazobactam in Post Operative Surgical Site Infection and Pancreatic Leak, sponsored by Tel-Aviv Sourasky Medical Center. Recruiting at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Tel-Aviv Sourasky Medical Center · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Surgical Wound Infection with a site in Israel — 4 open to participants now, 4 under way, none of them phase 3. Surgical Wound Infection · Israel.
Among the 18 studies in Surgical Wound Infection with a site in Israel, this one is the 11th largest by planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 in phase 4, and was the 18th registered.
747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.
Browse Surgical Wound Infection studies →4 of the 18 studies in Surgical Wound Infection with a site in Israel are open now. Recruiting first, the newest first:
Western Galilee Hospital-Nahariya · Sites in Israel
Ages 18+ · Women only · Healthy volunteers
Doron Kabiri · Sites in Israel
Ages 18+ · Women only · Healthy volunteers
Hadassah Medical Organization · Sites in Israel
Women only · Healthy volunteers
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 85 Surgical Wound Infection studies recruiting now, 62 (73%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 5 · Phase 4 5
First in 2007; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is close to the median of 200 across 583 interventional studies indexed under Surgical Wound Infection.
Median enrollment 320 across the 16 interventional studies, 862 across the 2 observational. Of the 11 that completed or were terminated, 7 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 18 have an industry lead sponsor. The 10 most frequent:
Tel-Aviv Sourasky Medical Center is the lead sponsor of 555 studies on the registry; 52 are open to participants now.
Tel-Aviv Sourasky Medical Center has 1 study filed under Surgical Wound Infection — fewer than ten, so there is no comparison to draw.
3 of the studies in Surgical Wound Infection with a site in Israel that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07311395Western Galilee Hospital-NahariyaLocal Subcutaneous Gentamicin for Prevention of Surgical Site Infection After Elective Cesarean Section | 2027-01-07 |
| NCT07483411Doron KabiriSkin Adhesive Plus Intra-cuticular Suture Versus Suture Alone for Cesarean Skin Closure | 2027-01-27 |
| NCT06454227Hadassah Medical OrganizationSubcutaneous Lavage in Cesarean Section | 2027-10-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 18 studies in Surgical Wound Infection with a site in Israel, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pancreaticoduodenectomy (Whipple procedure) is associated with substantial postoperative morbidity, mainly infectious complications and postoperative pancreatic fistula. Perioperative antibiotic prophylaxis is routine, but the optimal strategy for postoperative antibiotic administration is unclear, and practice varies between surgeons.
The objective of this study is to determine whether the duration of postoperative piperacillin-tazobactam (24 hours versus 5 days) affects postoperative infectious outcomes in patients undergoing pancreaticoduodenectomy.
This is a single-center, prospective, randomized clinical trial in adults undergoing open or minimally invasive (robotic) pancreaticoduodenectomy. All consented patients receive perioperative piperacillin-tazobactam according to institutional practice. After the operation is completed, patients who underwent pancreaticoduodenectomy and remain eligible are randomized by a computerized system, stratified by presence of a preoperative biliary stent and by surgical approach, to postoperative antibiotic treatment for 24 hours or 5 days.
The primary endpoint is the rate of postoperative infectious complications, comprising superficial wound infection, deep (fascial) surgical site infection, and intra-abdominal infection, defined according to CDC criteria, [within 30 days after surgery]. Participation does not change surgical technique, length of hospitalization, or routine follow-up.
As an exploratory component, intraoperative bile cultures are collected to describe biliary microbial profiles and antibiotic resistance patterns.
The study aims to provide high-quality evidence to guide postoperative antibiotic management and support more rational use of broad-spectrum antibiotics in pancreatic surgery.
BACKGROUND AND RATIONALE
Pancreaticoduodenectomy (Whipple procedure) is a standard surgical treatment for benign and malignant diseases of the pancreatic head and periampullary region. The operation carries high morbidity and mortality. The most common complications are postoperative infections and pancreatic fistula, occurring in approximately 30-50% of patients. These complications reduce quality of life, limit the ability to complete adjuvant chemotherapy, and are associated with lower overall survival.
Biliary infection, particularly after preoperative biliary stenting, is a major contributor to postoperative infections. Stenting alters the biliary microbial profile and often leads to colonization with organisms associated with higher rates of postoperative infection and pancreatic fistula. These organisms frequently show resistance to standard prophylactic antibiotics, which highlights the importance of matching antibiotic regimens to the patient's microbial profile.
Perioperative antibiotic prophylaxis is routinely administered during pancreatic surgery. However, continuation of antibiotics after surgery varies between clinicians and is left to the surgeon's discretion, without a defined protocol. Recent studies indicate that broad-spectrum antibiotics such as piperacillin-tazobactam (Tazocin) are superior to cephalosporins in reducing infections after Whipple surgery, particularly in patients with a preoperative biliary stent. However, the optimal duration of therapy remains unclear. Longer treatment may further reduce infections in high-risk populations, but raises concerns regarding antimicrobial resistance, adverse effects, and cost.
OBJECTIVE
To compare the efficacy of short-course (24 hours) versus extended (5 days) postoperative piperacillin-tazobactam in reducing infections after pancreaticoduodenectomy. By optimizing antibiotic duration, the study seeks to balance infection prevention and clinical outcomes against responsible antibiotic stewardship, and to propose a new standard for managing patients undergoing this operation.
STUDY DESIGN
Single-center, prospective, randomized, open-label clinical trial. A total of 200 participants will be enrolled at Tel Aviv Sourasky Medical Center, undergoing pancreaticoduodenectomy by an open or minimally invasive (robotic) approach.
Written informed consent is obtained before surgery. All participants receive piperacillin-tazobactam before skin incision and during surgery. After the operation is completed, patients in whom pancreaticoduodenectomy was successfully completed and who remain eligible are randomly assigned, using a computerized system, to one of two groups. Randomization is stratified by:
These factors were selected because of their potential impact on postoperative infectious risk. Patients in whom pancreaticoduodenectomy is not performed are not randomized and are not included in the study.
Because the antibiotic is ordered as a visible medical order and given intravenously during hospitalization, participants and investigators are aware of group allocation. Participation does not prolong the operation or the usual hospital stay.
PARTICIPANT SELECTION AND CONSENT
Eligible adults scheduled for Whipple surgery are approached in the preoperative clinic or during admission before surgery. Written informed consent is obtained after a full face-to-face explanation, with time for questions, using a digital consent process, or a paper form if the patient declines digital signing or technical problems occur.
Inclusion criteria:
Exclusion criteria:
Removal from the study (before or after randomization):
INTERVENTION AND DOSING
Intraoperative: piperacillin-tazobactam 4.5 g within 60 minutes before incision, with additional doses every 2-4 hours until the end of surgery, adjusted for renal function.
Postoperative: 4.5 g three times daily, or a reduced dose according to renal function, for 5 days (Group 1) or 24 hours (Group 2).
POSTOPERATIVE CARE AND FOLLOW-UP
Inpatient follow-up is the routine for Whipple surgery: daily physician rounds with history, vital signs, physical examination, drain output, and review of laboratory tests and imaging. Blood tests are routine on postoperative days 1 and 2, and thereafter at the discretion of the treating team. Decisions on CT imaging and on additional antibiotic treatment, regardless of study group, follow the algorithm-based care of the Dutch Pancreatic Cancer Group, agreed in advance by all pancreatic surgeons.
After discharge, participants are followed in the surgical clinic at 1, 3, 6, and 12 months after surgery, and annually thereafter.
OUTCOME MEASURES
Primary endpoint: rate of surgical site infection (SSI) within 30 days of surgery, comprising superficial incisional, deep incisional, and organ/space SSI according to CDC definitions.
Secondary endpoints:
DATA COLLECTION
Data are collected in coded form, with the coding key held separately by the principal investigator, and are not shared outside the hospital. Collected data include demographics; preoperative clinical variables (BMI, comorbidities, ASA score, biliary stent or drainage, neoadjuvant therapy, pathology); operative variables (approach, duration, pancreatic texture, duct size, blood loss, vascular reconstruction, bile culture results); postoperative course (length of stay, infections, pancreatic fistula grade, C. difficile infection, imaging, interventions, reoperation, other infectious and non-infectious complications); and follow-up to one year (late complications, cancer recurrence, date of last visit or death).
STATISTICAL ANALYSIS
Overall infection rate, infection rate by subtype, and pancreatic fistula rate are compared between the groups using the chi-square test. The same test is used for reoperation, invasive intervention, other postoperative complications, and C. difficile infection. Common bacteria and antibiotic sensitivity profiles are described. Cancer recurrence and overall survival are compared using Kaplan-Meier curves.
STUDY SIGNIFICANCE
This trial compares two durations of postoperative piperacillin-tazobactam in a standardized, randomized setting. The results are expected to guide postoperative antibiotic management, reduce infectious morbidity after pancreaticoduodenectomy, and support more rational use of broad-spectrum antibiotics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Piperacillin-tazobactam 4.5 g IV three times daily (or reduced dose according to renal function) for 5 days after the end of surgery, in addition to perioperative dosing before incision and during surgery.
Drug: piperacillin-tazobactam
Piperacillin-tazobactam 4.5 g IV three times daily (or reduced dose according to renal function) for 24 hours after the end of surgery, in addition to perioperative dosing before incision and during surgery.
Drug: piperacillin-tazobactam
Intravenous piperacillin-tazobactam. All participants receive 4.5 g (dose and interval adjusted for renal function) within 60 minutes before incision, with additional intraoperative doses every 2-4 hours until the end of surgery. After surgery, participants receive 4.5 g three times daily (or a reduced dose according to renal function) for either 5 days or 24 hours, according to randomization.
Also known as: Tazocin, Zosyn
Rate of surgical site infection (SSI) after pancreaticoduodenectomy
Proportion of participants with surgical site infection, comprising superficial incisional SSI, deep incisional SSI, and organ/space SSI (intra-abdominal infection), as defined by the CDC National Healthcare Safety Network criteria.
Time frame: Within 30 days after surgery
Overall early postoperative complication rate
roportion of participants with any postoperative complication, including pancreatic fistula, infectious complications other than surgical site infection (urinary tract infection, pneumonia, line sepsis), hemorrhage (requiring transfusion or intervention such as angiography), delayed gastric emptying, ileus or early small bowel obstruction, chyle leak, acute kidney injury, venous thromboembolism, and acute coronary syndrome (STEMI/non-STEMI).
Time frame: Within 30 days after surgery
Postoperative pancreatic fistula
Proportion of participants who develop a postoperative pancreatic fistula, graded A, B, or C according to the International Study Group on Pancreatic Fistula (ISGPS) definition.
Time frame: Within 30 days after surgery
Late postoperative complications
Proportion of participants with complications occurring after the early postoperative period (beyond 30 days), including: anastomotic stricture (biliary, pancreatic-enteric, or gastro/duodeno-enteric); anastomotic or marginal ulcer; late hemorrhage or pseudoaneurysm; delayed intra-abdominal collection or abscess; delayed or recurrent cholangitis; incisional hernia; small bowel obstruction or internal hernia; exocrine pancreatic insufficiency requiring enzyme replacement; new-onset or worsening diabetes mellitus; chronic diarrhea, malabsorption, or weight loss; portal or mesenteric vein thrombosis.
Time frame: Between 30 days and 1 year after surgery
Need for invasive intervention after surgery
Proportion of participants who require an invasive intervention after the operation (for example, percutaneous drainage or an angiographic procedure), excluding return to the operating room.
Time frame: Within 30 days after surgery
Early reoperation
Proportion of participants who require a return to the operating room for surgical revision or reintervention after the index operation, for any cause related to the index operation, during the early postoperative period.
Time frame: Within 30 days after surgery
Late reoperation
Proportion of participants who require a return to the operating room for surgical revision or reintervention after the early postoperative period (beyond 30 days), for any cause related to the index operation.
Time frame: Between 30 days and 1 year after surgery
Antibiotic-related adverse events, including Clostridioides difficile infection
Proportion of participants with adverse events and complications attributable to antibiotic administration, including Clostridioides difficile infection (CDT).
Time frame: Within 60 days after surgery
Microbial profile and antibiotic resistance
Organisms isolated and their antibiotic susceptibility and resistance profiles, from intraoperative bile cultures and from postoperative blood or other body fluid cultures taken when clinically indicated. Compared between participants with and without a preoperative biliary stent and between study groups.
Time frame: At surgery (bile cultures) and up to 60 days after surgery
Overall survival
Time from the date of surgery to death from any cause. Participants alive at last follow-up are censored at the date of last visit. Compared between study groups using Kaplan-Meier curves.
Time frame: Up to 5 years after surgery
Started Mar 2025 (actual). Primary completion is estimated for Dec 2028, 45 months after the start.
Of 45 non-industry phase 4 interventional studies under Surgical Wound Infection, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 51. This study's planned 45 months is above that.
Counting every sponsor, half of 47 studies reached it within 30 months; a quarter within 16 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tel-Aviv Sourasky Medical Center →